The FDA has approved AstraZeneca’s anifrolumab for adults with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy. This is the first new approval for these patients in 10 years, and just the second in the past 60 years.

Para acessar a publicação na íntegra clique aqui

Fonte:  658 | SEPTEMBER 2021 | volume 20 NEwS in BRiEf www.nature.com/nrd